Corporation
Boehringer Ingelheim Canada Ltd.
- Meetings this Parliament
- 18
- With MPs
- 5
- Since Nov 2021
- 45
- Active registrations
- 1
Most recent reported meeting: Sep 21, 2026.
Lobbying by Boehringer Ingelheim Canada Ltd.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Aug 18, 2026
Filed by Rithesh Mishra, Interim President and CEO
Lobbyists
- Andrew Ransom · Manager, Patient Access
- Annie Beauchemin · Head, Market Access
- Brad Thompson · Manager, External & Healthcare Affairs
- Eve Blanchet · Regional Manager/ QUE, Patient Access and Health Policy
- James Thompson · Manager, National Health Policy
- Mehmood Alibhai · Director of Patient Access & Healthcare Policy
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (2)Hide details
- Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).
- Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Registration 965031-371995-12. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Mark Lewis (27), Andrea Sambati (11), Rithesh Mishra (5), Ruta Stauskas (2).
-
Reported by Mark Lewis · In-house (corporation)
- Joanna Lam · Policy and Regional Affairs Advisor, Indigenous Services Canada (ISC)
Health
-
Reported by Ruta Stauskas · In-house (corporation)
- Stephen Ellis · MP, House of Commons
Health
-
Reported by Ruta Stauskas · In-house (corporation)
- Daniel Saad · Senior Policy Advisor, Prime Minister's Office (PMO)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Daniel macdonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
Health
-
Reported by Mark Lewis · In-house (corporation)
- Shawn Driscoll · Stakeholder Relations Advisor, House of Commons
- Darren Hall · Office of Leader of Opposition, House of Commons
Health
-
Reported by Mark Lewis · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
- Michelle Boudreau · Executive Director, Office of Pharmaceutical Management Strategies, Health Canada (HC)
Health
-
Reported by Mark Lewis · In-house (corporation)
- Allison Haley · Director of Parliamentary Affairs, House of Commons
Health
-
Reported by Mark Lewis · In-house (corporation)
- Helen Gao · Director of Policy, Indigenous Services Canada (ISC)
- Michelle Mujoomdar · Director, Specialty Pharmaceuticals, Health Canada (HC)
Health
-
Reported by Mark Lewis · In-house (corporation)
- renee bowers · Manager and Sr Policy Analyst, Indigenous Services Canada (ISC)
- Karen Fortin · Director, Indigenous Services Canada (ISC)
Health
-
Reported by Mark Lewis · In-house (corporation)
- Benoit Leduc · Manager, Socio Economic Info, Innovation, Science and Economic Development Canada (ISED)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Eric Costen · Senior ADM, Industry Sector, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Life Sciences and Biomanufacturing Branch, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Director, Biomanufacturing Branch, Strategy Directorate, Innovation, Science and Economic Development Canada (ISED)
Science and Technology
-
Reported by Andrea Sambati · In-house (corporation)
- Michelle Mujoomdar · Director, Specialty Pharmaceuticals, Health Canada (HC)
- Michelle Boudreau · Executive Director, Office of Pharmaceutical Management Strategies, Health Canada (HC)
- Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Michelle Boudreau · Executive Director, Office of Pharmaceutical Management Strategies, Health Canada (HC)
- Michelle Mujoomdar · Director, Specialty Pharmaceuticals, Health Canada (HC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Zachary Nixon · Senior Assistant, Stakeholder Relations & Regional Affairs, Global Affairs Canada (GAC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Zachary Nixon · Senior Special Assistant Stakeholder Relations and Regional Affairs, Global Affairs Canada (GAC)
- Michelle Boudreau · Executive Director, Health Canada (HC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Jamie Kippen · Chief of Staff, Health Canada (HC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Adam van Koeverden · Member of Parliament
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Adam van Koeverden · Member of Parliament
- Stephen Ellis · Member of Parliament, House of Commons
- Jamie Kippen · Chief of Staff, Health Canada (HC)
Health
-
Reported by Andrea Sambati · In-house (corporation)
- Ed Fast · Member of Parliament, House of Commons
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.